app.rxdatalab.com · Free public feature
Regulatory filings linked to clinical programs and markets. Trials, SEC filings, insider activity, and market data from primary sources.
BioHedge
Hedge fund positioning from Schedule 13D/13G filings. Each position cross-referenced with clinical trial events, regulatory filings, and insider trades. Free public view — the full platform adds company profiles, trial history, competitive landscape, and financing tracker for 500+ biotech companies.
Activity Summary
Multi-Fund Activity
Companies with two or more institutional investors filing in the same period.
Filing Volume by Week
|
Filed
|
Fund | Company | Position | Gap |
|---|---|---|---|---|
|
Sep 16, 2026
Event: 09/14/2026
Filed: Sep 16, 2026 |
ONC
BEONE MEDICINES LTD-ADR
|
owns 7.8% ▼-0.2 | 93d | |
|
ONC
BEONE MEDICINES LTD-ADR
7.8%
▼-0.2
93d
|
||||
|
Sep 10, 2026
Event: 09/08/2026
Filed: Sep 10, 2026 |
D
OrbiMed
|
Braveheart Bio, Inc.
|
owns 13.5% | — |
|
Braveheart Bio, Inc.
13.5%
|
||||
|
Sep 10, 2026
Event: 09/08/2026
Filed: Sep 10, 2026 |
TRDA
Entrada Therapeutics, Inc.
|
owns 9.9% | — | |
|
TRDA
Entrada Therapeutics, Inc.
9.9%
|
||||
|
Sep 10, 2026
Event: 09/02/2026
Filed: Sep 10, 2026 |
LGVN
Longeveron Inc.
|
owns 6.3% NEW | — | |
|
LGVN
Longeveron Inc.
6.3%
NEW
|
||||
|
Sep 8, 2026
Event: 08/31/2026
Filed: Sep 8, 2026 |
TENX
TENAX THERAPEUTICS, INC.
|
owns 14.0% NEW | — | |
|
TENX
TENAX THERAPEUTICS, INC.
14.0%
NEW
|
||||
|
Sep 4, 2026
Event: 09/04/2026
Filed: Sep 4, 2026 |
ABUS
Arbutus Biopharma Corp
|
owns 8.0% NEW | — | |
|
ABUS
Arbutus Biopharma Corp
8.0%
NEW
|
||||
|
Sep 4, 2026
Event: 08/31/2026
Filed: Sep 4, 2026 |
NPCE
NeuroPace
|
owns 12.2% | — | |
|
NPCE
NeuroPace
12.2%
|
||||
|
Sep 3, 2026
Event: 09/03/2026
Filed: Sep 3, 2026 |
APGE
Apogee Therapeutics, Inc.
|
owns 0.0% EXIT | 72d | |
|
APGE
Apogee Therapeutics, Inc.
0.0%
EXIT
72d
|
||||
|
Aug 27, 2026
Event: 08/17/2026
Filed: Aug 27, 2026 |
TENX
TENAX THERAPEUTICS, INC.
|
owns 5.3% NEW | — | |
|
TENX
TENAX THERAPEUTICS, INC.
5.3%
NEW
|
||||
|
Aug 27, 2026
Event: 08/26/2026
Filed: Aug 27, 2026 |
IMTX
Immatics N.V.
|
owns 7.6% | — | |
|
IMTX
Immatics N.V.
7.6%
|
||||
Understanding Schedule 13D and 13G Filings
Schedule 13D and 13G filings are SEC disclosures required when an investor acquires more than 5% of a company's outstanding shares.
Schedule 13D (Activist)
Filed when an investor may seek to influence management, board composition, or corporate strategy. Requires disclosure of investment purpose and plans.
Schedule 13G (Passive)
Filed by passive investors (mutual funds, index funds, institutions) with no intent to influence. Simpler filing requirements.
Gap column: Days since previous filing for the same fund+company pair.
Data source: SEC EDGAR. Filings typically available within 4 hours of submission.
This page reflects disclosed ownership changes only. Absence of activity does not imply absence of interest.
Intelligence Platform
Every event, in context.
Cross-reference each company's trial history, SEC filings, insider trades, and fund positioning in one view. Traceable to primary sources.